부산대학교 도서관

Introduction:Centhaquine increased mean arterial pressure and cardiac output and decreased systemic vascular resistance during resuscitation of hemorrhagic shock. Its safety and tolerability has been demonstrated in humans (CTRI/2014/06/004647).Methods:A prospective, multi-centric, randomized, double-blind, parallel, saline controlled study was carried out (CTRI/2017/03/008184). Out of 137 subjects screened 50 met inclusion and exclusion criteria and were included in the study. All subjects received standard treatment for shock and were randomly assigned to either control group that received standard treatment along with normal saline or centhaquine group that received standard treatment along with centhaquine. In control group 16 male and 6 female and in centhaquine group 18 male and 5 female subjects competed the study.Results:Demographics of patients in both groups was comparable. Hemoglobin level was 9.38 ? 0.71 g/dL in control group, and 8.73 ? 0.55 g/dL in centhaquine group at the time of inclusion in the study. The total volume of fluids and blood products administered in the first 48 hours were similar in control and centhaquine group. Patients in control group spent 1.96 ? 1.10 days while those in centhaquine group spent 0.89 ? 0.45 days on ventilator. In the first 48 hours of resuscitation control group patients received 9.39 ? 4.28 mg while centhaquine group received 3.12 ? 2.18 mg of vasopressors. Systolic blood pressure in control group improved (Mean diff. 18.41; p=0.0036), while in centhaquine group a more significant (Mean diff. 34.13; p<0.0001) increase in systolic pressure was observed 48 hours after resuscitation compared to baseline. A significant (Mean diff. 18.13; p<0.0001) increase was observed in diastolic blood pressure in centhaquine group and not in control. At day 3 of resuscitation blood lactate levels (mmol/L) decreased significantly (301% p=0.0012) in centhaquine group while an insignificant (p=0.7729) decrease of 134% was observed in control group. Two out of 15 patients died in control and none in centhaquine group. No incidence of drug related adverse event occurred.Conclusions:Centhaquine could be a first-in-class resuscitative agent for hemorrhagic shock.